pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
Endpoints·3h ago·1 min read
save

Devoted Health secures $1.2 billion in new funding to fuel senior member growth

Oct 1, 2026·read at Endpoints ↗DealPositive

Devoted Health, a Medicare Advantage insurer and medical group, announced a fresh capital injection of nearly $1.2 billion.

The financing round includes a $555 million Series G investment along with additional contributions from existing and new investors.

The company said the new funds will support its rapid expansion after enrolling hundreds of thousands of senior members this year.

The sizable raise highlights strong investor confidence in Devoted Health’s health‑tech approach to serving Medicare beneficiaries.

source

This writeup was produced by pharmadog from original reporting by Endpoints.

Original headline: “Insurer startup Devoted Health raises $1.2B as it revs up growth”

read at Endpoints ↗
89 words · retrieved 1h ago
sharex / twitterlinkedin

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?

companies & drugs in this story

no entities indexed yet

related stories

  • 55m agoUnited Therapeutics' legal victory; BMS' Camzyos approved for kidsEndpoints
  • 58m agoIs AI jacking up healthcare costs?Endpoints
  • 2h agoLilly pulls back from Foghorn's synthetic lethality work as biotech sheds 40% of staffEndpoints
  • 2h ago#EASD26: Regeneron's antibody helps patients regain muscle after stopping GLP-1 therapyEndpoints
  • 2h agoQ&A: Anthropic's life sciences team talk Claude's first scientific discoveryEndpoints